Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

ClinicalTrials.gov ID: NCT05445128

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05445128. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.

Study identification

NCT ID: NCT05445128
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Ensoma; Industry
Enrollment: 1 participant

Conditions and interventions

Conditions

Sickle Cell Disease

Interventions

MGTA-145 Biological
Plerixafor Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years to 35 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 24, 2022 (Actual)
Primary completion: Dec 8, 2022 (Actual)
Completion: Feb 2, 2023 (Actual)
Last update posted: Jul 25, 2025

2022 – 2023

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
National Institutes of Health	Bethesda	Maryland	20892	—
Boston Children's Hospital	Boston	Massachusetts	02115	—
St. Jude Children's Research Hospital	Memphis	Tennessee	38105	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05445128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 25, 2025 · Synced Nov 15, 2026